Anjiolab Restarts KOSDAQ Listing After Lead Manager Change

[Asia Economy Reporter Eunmo Koo] Angiolab, a KONEX-listed company, is reattempting to list on the KOSDAQ market.

On the 1st, Angiolab announced that it will change its listing sponsor from NH Investment & Securities to Daishin Securities. Marking this change in sponsor, the company will actively prepare for the KOSDAQ listing and plans to reapply for the technology evaluation in the second half of next year.

Angiolab focuses on research of natural product pharmaceuticals and antibody drugs based on its vascular regeneration discovery technology, developing treatments for various diseases. It also sells health functional foods approved by the Ministry of Food and Drug Safety. Currently, it is conducting Phase 2 clinical trials targeting four diseases: wet age-related macular degeneration, non-alcoholic steatohepatitis, exudative otitis media, and periodontal disease. In January, it received 'A' and 'BBB' grades from a professional evaluation agency designated by the Korea Exchange, recognizing its excellent technological capabilities.

The technology evaluation, which allows the company to request listing examination, expired as of July, and the company plans to verify its technology again through reapplication next year. The company intends to smoothly complete the technology evaluation and actively pursue a technology-special listing.

An Angiolab representative stated, “Our excellent technology has been objectively proven through the already conducted technology evaluation, and about three out of the four ongoing clinical trials are expected to be completed next year, showing visible results. With this change in sponsor, we will proceed with a more successful initial public offering.”

This content was produced with the assistance of AI translation services.